Biology

HitGen featuring 200㎡ BSL-2 laboratories, SPF animal facilities, and NGS platforms. Through the strategic convergence of cutting-edge facilities and systematic research capabilities, covering early discovery to preclinical development services.

Protein Science: HitGen offers a comprehensive protein expression platform using E. coli, insect cells, mammalian cells, and yeast. We specialize in custom protein production with rational construct design, including tag options, functional labeling, and post-translational modifications.

NGS and Bioinformatics: Our flexible solutions cover a wide range of sequencing capacities, from 400M to 10,000M reads, tailored to your specific needs. With an average Q30 score exceeding 92% and a turnaround time of under two days, we deliver both speed and reliability for your research.

Cell Biology: HitGen specialize in delivering cell biology research solutions for global pharmaceutical enterprises and academic institutions, including cell model development, target validation, drug evaluation, and functional mechanism analysis.

Pre-clinical Studies: HitGen's In Vivo platform provides in vivo pharmacokinetics, efficacy and non-GLP toxicity evaluation services, efficacy models covering tumor, autoimmune and inflammation, kidney disease, metabolic diseases, etc.

Bioanalysis: Bioanalysis services relying on HitGen's one-stop service platform for drug development, cover all stages from drug screening to PCC determination, including bioanalysis in pharmacokinetics, pharmacodynamics and toxicology.

Thanks for reading!

For more details on how we can advance your innovative drug discovery projects

Sites: HitGen Inc.

Building C2, NO.8, Huigu 1st East Road
Tianfu International Bio-Town,
Shuangliu District, Chengdu City,
Sichuan Province,P.R. China

Tel : +86-28-8519-7385

HitGen Pharmaceuticals Inc.(US Subsidiary)

Tel : +1-(508)-840-9646

Vernalis (R&D) Limited (UK Subsidiary)

Granta Park,Great Abington
Cambridge,CB21 6GB
United Kingdom

Tel : +44(0)1223-895555

Contact: Business Inquiry : bd@hitgen.com; Investor Relations : investors@hitgen.com; Media : media@hitgen.com; Career and Jobs : human.resources@hitgen.com

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information